Abstract
Characterization of cytolytic T lymphocyte (CTL) responses to tumor antigens has been impeded by a lack of direct assays of CTL activity. We have synthesized reagents ("tetramers") that specifically stain CTLs recognizing melanoma antigens. Tetramer staining of tumor-infiltrated lymph nodes ex vivo revealed high frequencies of tumor-specific CTLs which were antigen-experienced by surface phenotype. In vitro culture of lymph node cells with cytokines resulted in very large expansions of tumor-specific CTLs that were dependent on the presence of tumor cells in the lymph nodes. Tetramer-guided sorting by flow cytometer allowed isolation of melanoma-specific CTLs and confirmation of their specificity and their ability to lyse autologous tumor cells. Our results demonstrate the value of these novel reagents for monitoring tumor-specific CTL responses and for generating CTLs for adoptive immunotherapy. These data also indicate that strong CTL responses to melanoma often occur in vivo, and that the reactive CTLs have substantial proliferative and tumoricidal potential.
MeSH Terms
Adult
Aged
Amino Acid Sequence
Antigens, Neoplasm/genetics,metabolism
Female
Histocompatibility Antigens Class I/chemistry,metabolism
Humans
Immunotherapy, Adoptive
Indicators and Reagents
Lymphatic Metastasis/immunology,pathology
Lymphocytes, Tumor-Infiltrating/immunology,pathology
MART-1 Antigen
Male
Melanoma/immunology,secondary,therapy
Middle Aged
Monophenol Monooxygenase/genetics,immunology
Neoplasm Proteins/genetics,immunology
Peptide Fragments/genetics,immunology
Protein Conformation
Staining and Labeling
T-Lymphocytes, Cytotoxic/immunology,pathology
Chemicals
Antigens, Neoplasm
Histocompatibility Antigens Class I
Indicators and Reagents
MART-1 Antigen
MLANA protein, human
Neoplasm Proteins
Peptide Fragments
Monophenol Monooxygenase
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Romero P
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Swizerland.
[email protected]
Dunbar P R
Valmori D
Pittet M
Ogg G S
Rimoldi D
Chen J L
Liénard D
Cerottini J C
Cerundolo V
References (22)
22 references, click to expand
-
Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28.
Hum Immunol. 1981 Dec;3(4):277-99
PMID: 7035415
-
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy.
Mol Med Today. 1998 Jul;4(7):305-12
PMID: 9743992
-
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.
Science. 1992 Dec 11;258(5089):1795-8
PMID: 1465616
-
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
J Immunol. 1995 Apr 15;154(8):3961-8
PMID: 7706734
-
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.
Immunol Today. 1995 Oct;16(10):487-94
PMID: 7576053
-
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
J Exp Med. 1996 Feb 1;183(2):527-34
PMID: 8627164
-
Infrequent expression of the MAGE gene family in uveal melanomas.
Int J Cancer. 1996 Jun 11;66(6):738-42
PMID: 8647642
-
Phenotypic analysis of antigen-specific T lymphocytes.
Science. 1996 Oct 4;274(5284):94-6
PMID: 8810254
-
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.
J Immunol. 1996 Oct 1;157(7):3030-8
PMID: 8816412
-
Human tumor antigens recognized by T cells.
Curr Opin Immunol. 1996 Oct;8(5):628-36
PMID: 8902387
-
Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.
Springer Semin Immunopathol. 1996;18(2):185-98
PMID: 8908699
-
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Science. 1996 Nov 22;274(5291):1363-6
PMID: 8910274
-
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Immunol Today. 1997 Apr;18(4):175-82
PMID: 9136454
-
Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
Cancer Res. 1997 Aug 1;57(15):3223-9
PMID: 9242453
-
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
J Immunol. 1997 Sep 1;159(5):2366-74
PMID: 9278327
-
In vitro responses of human CD45R0brightRA- and CD45R0-RAbright T cell subsets and their relationship to memory and naive T cells.
Eur J Immunol. 1997 Sep;27(9):2383-90
PMID: 9341784
-
Prospects for adoptive T cell therapy.
Curr Opin Immunol. 1997 Oct;9(5):702-8
PMID: 9368780
-
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
Int J Cancer. 1998 Feb 9;75(4):517-24
PMID: 9466650
-
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
J Immunol. 1998 Feb 15;160(4):1750-8
PMID: 9469433
-
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
Science. 1998 Mar 27;279(5359):2103-6
PMID: 9516110
-
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.
Curr Biol. 1998 Mar 26;8(7):413-6
PMID: 9545200
-
Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.
Lancet. 1991 Nov 16;338(8777):1227-9
PMID: 1719320